Literature DB >> 19946197

Rush specific oral tolerance induction in school-age children with severe egg allergy: one year follow up.

Naoka Itoh1, Yasuharu Itagaki, Kazuyuki Kurihara.   

Abstract

BACKGROUND: At present, the only treatment for food allergy is to avoid the allergy-causing food. Some trials of specific oral tolerance induction (SOTI) have been carried out, but the rate of tolerance induction was low despite long treatment periods, at least 3 months to several years. A new type of treatment is long desired. The objectives of this study are to perform our rush SOTI for school-age patients with severe egg allergy, and to evaluate the safety and efficacy of this method for one year.
METHODS: Six school-age children (7-12 years of age) with severe IgE-mediated egg allergy confirmed by double-blind, placebo-controlled food challenge (DBPCFC) underwent rush SOTI, in which patients ingested increasing doses of egg several times every day. After rush SOTI, patients ingested the maintenance dose of egg at least twice a week.
RESULTS: In DBPCFC, the median threshold dose of egg white inducing allergic reactions was 0.152 g (0.012-0.360 g). All subjects acquired tolerance to more than one whole egg (60 g). It took only 12 days (9-18 days). None experienced any serious reaction. We observed a decrease in IL-10 and an increase in TGF-beta1 at 6 months and a decrease in egg-specific IgE and an increase in egg white-specific IgG4 at 12 months after rush SOTI in blood. All subjects have been able to ingest more than one whole egg ever since.
CONCLUSIONS: Our rush SOTI is a safe and effective treatment for severe food allergy since only a few weeks are needed to acquire tolerance. It would replace allergen avoidance as the treatment for food allergy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19946197     DOI: 10.2332/allergolint.09-OA-0107

Source DB:  PubMed          Journal:  Allergol Int        ISSN: 1323-8930            Impact factor:   5.836


  26 in total

Review 1.  Oral and Sublingual Immunotherapy for Treatment of IgE-Mediated Food Allergy.

Authors:  Amy M Scurlock
Journal:  Clin Rev Allergy Immunol       Date:  2018-10       Impact factor: 8.667

Review 2.  Update on oral immunotherapy for egg allergy.

Authors:  François Graham; Natacha Tardio; Louis Paradis; Anne Des Roches; Philippe Bégin
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

Review 3.  The Heterogeneity of Oral Immunotherapy Clinical Trials: Implications and Future Directions.

Authors:  Christina S K Yee; Rima Rachid
Journal:  Curr Allergy Asthma Rep       Date:  2016-04       Impact factor: 4.806

Review 4.  Immunotherapy in food allergy.

Authors:  Toral Kamdar; Paul J Bryce
Journal:  Immunotherapy       Date:  2010-05       Impact factor: 4.196

Review 5.  Immunological mechanisms for desensitization and tolerance in food allergy.

Authors:  Rima Rachid; Dale T Umetsu
Journal:  Semin Immunopathol       Date:  2012-07-21       Impact factor: 9.623

Review 6.  Emerging therapies for food allergy.

Authors:  Corinne A Keet; Robert A Wood
Journal:  J Clin Invest       Date:  2014-05-01       Impact factor: 14.808

7.  Individualized IgE-based dosing of egg oral immunotherapy and the development of tolerance.

Authors:  Brian P Vickery; Laurent Pons; Michael Kulis; Pamela Steele; Stacie M Jones; A Wesley Burks
Journal:  Ann Allergy Asthma Immunol       Date:  2010-12       Impact factor: 6.347

Review 8.  Oral immunotherapy for the treatment of food allergy.

Authors:  Philippe Begin; R Sharon Chinthrajah; Kari C Nadeau
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 9.  Clinical practice: Allergen-specific immunotherapy in children: facts and FAQs.

Authors:  Zsolt Szépfalusi; Saskia Gruber; Thomas Eiwegger; Eleonora Dehlink
Journal:  Eur J Pediatr       Date:  2010-12-10       Impact factor: 3.183

Review 10.  Oral Immunotherapy for Treatment of Immunoglobulin E-Mediated Food Allergy: The Transition to Clinical Practice.

Authors:  Giovanni B Pajno; Linda Cox; Lucia Caminiti; Vincenzo Ramistella; Giuseppe Crisafulli
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2014-06-01       Impact factor: 1.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.